Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Colbourne JRM, Fisher OM, Mo S, Rigas GS, Talbot ML
Changes to your care may be made and follow-up tests may be conducted to ensure your potassium has returned to safe levels
The CheckMate 238 (NCT02388906) trial compared nivolumab with ipi10 and found that nivolumab produced superior RFS and had a more tolerable safety profile.[24] Pembrolizumab produced superior RFS compared with placebo, with data on OS still maturing in the MK-3475-054/KEYNOTE-054 trial (NCT02362594).[25] Dabrafenib plus trametinib produced superior RFS compared with placebo, with data on OS still maturing in the COMBI-AD trial (NCT01682083).[26] Single-agent BRAF-inhibitor therapy with vemurafenib did not show improved RFS compared with placebo in the BRIM8 trial (NCT01667419).[27] The benefit of immunotherapy with ipilimumab, nivolumab, and pembrolizumab has been seen regardless of programmed death-ligand 1 (PD-L1) expression or the presence of BRAF pathogenic variants
Nat Genet 55:255267
US$ 20.34
US$ 22.50
US$ 21.56
US$ 27.88
US$ 20.97
US$ 26.47
US$ 22.46
US$ 27.06
